Brought to you by 
Cell Pathways sells Sinclair's Gelclair; deal terminated
18 Jun 2014
Executive Summary
Cell Pathways (cancer therapeutics) will exclusively distribute UK company Sinclair Pharmaceuticals Ltd.'s (niche pharmaceutical products) 510k approved Gelclair (polyvinylpyrrolidone and sodium hyaluronate) oral pain gel to North America.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cell Pathways sells Sinclair's Gelclair; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice